Evidence map›Paper›PMID 40107663›Full record

SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2025

Comorbidities in the idiopathic pulmonary fibrosis and progressive pulmonary fibrosis trial population: a systematic review and meta-analysis.

Tyson M Walters, Marcus C H Leong, Sydney B Montesi, Christopher J Ryerson, Yet H Khor

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tyson M WaltersDepartment of Medicine, Austin Health, Heidelberg, Australia.ORCID https://orcid.org/0000-0002-3392-0116
Marcus C H LeongFaculty of Medicine, University of Melbourne, Melbourne, Australia.ORCID https://orcid.org/0009-0009-7313-2614
Sydney B MontesiDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA.
Christopher J RyersonDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Yet H KhorFaculty of Medicine, University of Melbourne, Melbourne, Australia yet.khor@monash.edu.ORCID https://orcid.org/0000-0002-5434-9342

Funding

Vascular Leak and Outcomes in IPFK23HL150331 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MONTESI, SYDNEY · 2020 to 2024
$887k
NHLBI NIH HHS K23 HL150331
6 · The paper itself

Abstract

backgroundComorbidities can affect drug tolerability and health outcomes in patients with fibrotic interstitial lung disease. This systematic review and meta-analysis evaluated the types and prevalence of comorbidities amongst participants in pharmaceutical randomised controlled trials (RCTs) of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

methodsOvid Medline, Embase and CENTRAL databases were searched to identify phase II and III pharmaceutical RCTs of IPF or PPF. Reporting of comorbidities was evaluated, with meta-analyses being performed for the prevalence of different conditions.

results34 articles were included, with 23 unique trials for IPF and one for PPF. A mean of 14 (range 1-44) comorbidities per study was reported in the IPF RCTs, with 11 being reported in the PPF RCT. Common comorbidities in the IPF RCT cohorts were systemic hypertension (pooled prevalence 45%, 95% CI 39-50%), hyperlipidaemia (38%, 95% CI 27-49%), gastro-oesophageal reflux disease (45%, 95% CI 36-54%), ischaemic heart disease (18%, 95% CI 13-42%) and diabetes mellitus (16%, 95% CI 13-20%). The PPF trial cohort had similar types and prevalence of comorbidities to those reported in the IPF trial cohorts.

conclusionsReporting of comorbidities varied across previous IPF RCTs, with limited data available for PPF. Prevalence of comorbidities reported in the IPF and PPF trial cohorts appear to be lower than those reported in prospective patient registries. There is a need for careful consideration of trial eligibility criteria with detailed reporting of comorbidities in future pharmaceutical RCTs to better understand the applicability of trial findings to real-world patients.

Indexed as

Idiopathic Pulmonary FibrosisComorbidityDisease ProgressionHumansPrevalenceRandomized Controlled Trials as TopicRisk FactorsTreatment Outcome

Identifiers

PMID40107663
PMCPMC11920886

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.